BioNexus Gene Lab Corp (BGLC)
Q2-CY2026Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014
Balance Sheet Date2025-Dec-312025-Sep-302025-Jun-302025-Mar-312024-Dec-312024-Sep-302024-Jun-302024-Mar-312023-Dec-312023-Sep-302023-Jun-302023-Mar-312022-Dec-312022-Sep-302022-Jun-302022-Mar-312021-Dec-312021-Sep-302021-Jun-302021-Mar-312020-Dec-312020-Sep-302020-Jun-302020-Mar-312019-Dec-312019-Sep-302019-Jun-302019-Mar-31
Fiscal PeriodQ4-FY2025Q3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024Q3-FY2024Q2-FY2024Q1-FY2024Q4-FY2023Q3-FY2023Q2-FY2023Q1-FY2023Q4-FY2022Q3-FY2022Q2-FY2022Q1-FY2022Q4-FY2021Q3-FY2021Q2-FY2021Q1-FY2021Q4-FY2020Q3-FY2020Q2-FY2020Q1-FY2020Q4-FY2019Q3-FY2019Q2-FY2019Q1-FY2019
Operating Cash Flow961,062$(1,237,465$)(737,907$)(824,072$)219,203$(1,603,035$)(672,275$)(37,153$)(782,526$)(899,345$)(22,044$)(116,518$)476,739$308,891$(195,969$)(37,839$)483,007$346,046$(905,143$)115,428$932,482$754,744$(157,198$)(977,348$)(58,362$)(57,415$)(52,935$)(48,561$)243,787$176,527$(20,833$)(673,561$)
Investing Cash Flow(5,717$)994,646$(28,532$)(15,646$)554,402$(203,160$)63,310$3,650$(1,425,378$)(360,710$)(3,058$)(5,056$)(49,903$)18,360$(221,822$)(197,133$)(76,289$)(88,757$)(59,879$)(295,826$)(416,505$)4,386$19,862$1,712,247$(7,145$)3,532$5,427$(14,631$)(17,297$)2,453$(6,723$)(30,134$)
Purchases of Property and Equipment977$5,483$21,459$9,052$4,022$1,833$21,945$937$134,003$14,356$102$17,027$3,660$1,293$32,191$1,279$410$666$807$421,316$0$(2$)307$7,145$(3,532$)(14,631$)(17,292$)(46,806$)
Financing Cash Flow266,544$34,187$(1,030$)(860$)(142,387$)(55,982$)175,414$26,930$531,733$5,747,418$(1,779$)(2,273$)(1,736$)(4,959$)(6,081$)(8,632$)(8,550$)2,256$2,186$(2,990$)(6,399$)(73,472$)(98,632$)(5,095$)(3,606$)(427,857$)(67,350$)121,468$1,116,681$
End Cash Position2,486,383$1,153,121$814,179$2,089,438$2,886,966$4,137,219$5,414,033$4,438,694$4,517,710$6,146,883$1,758,680$1,973,212$2,118,864$1,462,269$1,340,331$1,844,322$2,123,919$1,700,396$1,482,705$2,474,659$2,787,692$2,190,072$1,287,111$1,396,747$859,076$977,149$1,140,387$1,260,239$1,416,242$
Exchange Rate Effect(92,598$)28,535$215,220$43,050$(409,601$)565,220$(42,936$)(72,443$)46,998$(99,160$)(185,218$)(22,299$)232,032$(203,577$)(44,625$)21,764$(33,517$)
Dividends Paid
Unlevered Free Cash Flow960,085$(1,242,948$)(759,366$)(833,124$)215,181$(1,603,035$)(674,108$)(59,098$)(783,463$)(1,033,348$)(36,400$)(116,620$)459,712$305,231$(197,262$)(70,030$)481,728$345,636$(905,809$)114,621$511,166$754,744$(157,196$)(977,655$)(65,507$)(53,883$)(52,935$)(33,930$)261,079$223,333$(20,833$)(673,561$)